Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19208831 | 0.90 | MEN1 (0.36) | KMT2ALMNAALDH1A1RAB9AGAA | |
| SCHEMBL19208866 | 0.90 | MEN1 (0.36) | KMT2ALMNAALDH1A1RAB9AGAA | |
| SCHEMBL15166729 | 0.90 | MEN1 (0.36) | KMT2ALMNAALDH1A1RAB9AGAA | |
| SCHEMBL22898168 | 0.88 | P4HB (0.37) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL17174548 | 0.87 | DDB1 (0.39) | KMT2AALDH1A1DDB1CRBNNR1H2 | |
| SCHEMBL17174551 | 0.87 | DDB1 (0.39) | KMT2AALDH1A1DDB1CRBNNR1H2 | |
| SCHEMBL17174550 | 0.87 | DDB1 (0.39) | KMT2AALDH1A1DDB1CRBNNR1H2 | |
| SCHEMBL17174481 | 0.86 | DDB1 (0.38) | ALDH1A1DDB1CRBNNR1H2NR1H3 | |
| SCHEMBL17162572 | 0.86 | DDB1 (0.38) | ALDH1A1DDB1CRBNNR1H2NR1H3 | |
| SCHEMBL17174477 | 0.86 | DDB1 (0.38) | ALDH1A1DDB1CRBNNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-3831839-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-07-26 | — | — | EP | disclosed |
| EP-3831839-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-07-26 | — | — | EP | disclosed |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| EP-3831839-A2 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | ViiV Healthcare UK (No.5) Limited (GB) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831839-A2 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | ViiV Healthcare UK (No.5) Limited (GB) | 2021-06-09 | — | — | EP | disclosed |
| EP-3411381-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3411381-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-24 | — | — | US | disclosed |
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| EP-3411381-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134596-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134596-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | KMT2A 4547/4885TDP1 3081/4885SLC6A2 4795/4885 |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | KMT2A 4547/4885TDP1 3081/4885SLC6A2 4795/4885 |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | KMT2A 4547/4885TDP1 3081/4885SLC6A2 4795/4885 |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | KMT2A 4547/4885TDP1 3081/4885SLC6A2 4795/4885 |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | KMT2A 4547/4885TDP1 3081/4885SLC6A2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.